Special Issue

Targeted Therapies for Acute Leukemias

Message from the Guest Editor

Targeted therapies aim to interfere with the molecular pathways that drive the growth and survival of leukemia cells, while simultaneously mitigating any adverse effects on healthy cells. Several such agents have revolutionized treatment approaches and improved outcomes for many patients with acute leukemias. Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Recent advances have significantly impacted treatment options. Acute lymphoblastic leukemia (ALL) is the most common acute leukemia in children. The targeted agents used in B-ALL are tyrosine kinase inhibitors when Philadelphia-positive, rituximab, blinatumomab, inotuzumab ozogamicin and, most recently, chimeric antigen receptor (CAR)-T cell therapies. Nevertheless, questions remain about optimal sequencing, effective combinations, maintenance therapy post-remission, especially in AML, and treatment options post-CAR-T cell therapy failure in ALL. This Special Issue focuses on known or developing targeted treatments in acute leukemias to provide clinicians a comprehensive perspective.

Guest Editor

Dr. Eleftheria Hatzimichael

Department of Hematology, Faculty of Medicine, University of Ioannina, Stavros Niarchos Avenue, 45110 Ioannina, Greece

Deadline for manuscript submissions

closed (31 May 2025)

Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/200556

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

mdpi.com/journal/diseases

Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/diseases

About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets. *Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino
Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli
Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

MDPI